Spatiotemporal Release of Reactive Oxygen Species and NO for Overcoming Biofilm Heterogeneity. (4th July 2022)

• Record Type: Journal Article
• Authors: Han, Xue; Lou, Qi; Feng, Feng; Xu, Guanhua; Hong, Song; Yao, Li; Qin, Shijie; Wu, Dazhuan; Ouyang, Xiaoping; Zhang, Zhiguo; Wang, Xiuyu
• Is Part Of: Angewandte Chemie. Volume 134:Number 33(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-04
• Subjects: Biofilms -- Drug Design -- Heterogeneity -- Pharmacokinetic Complementarity -- Yolk–Shell Nanoplatform; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.202202559
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: The heterogeneity in biofilms is a major challenge in biofilm therapies due to different susceptibility of bacteria and extracellular polymeric substances (EPS) to antibacterial agents. Here, we describe a therapeutic strategy that overcame biofilm heterogeneity, where antibacterial agent (NO) and EPS dispersant (reactive oxygen species (ROS)‐inducing Fe 3+ ) were separately loaded in the yolk and shell compartment of a yolk–shell nanoplatform. Compared with traditional combinational chemotherapies which suffer from inconsistent pharmacokinetics profiles, this strategy drew on the pharmacokinetic complementarity of ROS and NO, where ROS with a short diffusion distance and a high redox potential corrupted the EPS, facilitating NO, which has a long diffusion distance and a broad antimicrobial spectrum, to penetrate the biofilm and eliminate the resident bacteria. Additionally, the construction of a three‐dimensional spherical biofilm model is novel and clinically relevant. Abstract : A therapeutic strategy to overcome biofilm heterogeneity is presented, in which antibacterial agent (NO) and extracellular polymeric substances (EPS) dispersant (reactive oxygen species (ROS)‐inducing Fe 3+ ) are separately loaded in the yolk and shell compartment of a yolk–shell nanoplatform. The spatiotemporally ordered release manner and pharmacokinetic complementarity of ROS and NO improve the anti‐biofilm outcome synergistically.